Drug Information

Drug General Information
Drug ID
D0D4OS
Former ID
DNCL001727
Drug Name
VM-202
Indication Angina pectoris; Peripheral arterial disease [ICD9: 413, 443; ICD10:I20, I73] Phase 3 [525174]
Company
ViroMed
Target and Pathway
Target(s) Hepatocyte growth factor Target Info Modulator [529590]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
PI3K-Akt signaling pathway
Focal adhesion
Malaria
Pathways in cancer
Proteoglycans in cancer
Renal cell carcinoma
Melanoma
NetPath Pathway EGFR1 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
TNFalpha Signaling Pathway
Pathway Interaction Database Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
Arf6 signaling events
Signaling events mediated by TCPTP
Direct p53 effectors
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
Syndecan-1-mediated signaling events
Stabilization and expansion of the E-cadherin adherens junction
FGF signaling pathway
Reactome Platelet degranulation
Interleukin-7 signaling
WikiPathways Signaling of Hepatocyte Growth Factor Receptor
Focal Adhesion
NRF2 pathway
Nuclear Receptors Meta-Pathway
Extracellular vesicle-mediated signaling in recipient cells
Differentiation Pathway
Interleukin-7 signaling
Prostate Cancer
References
Ref 525174ClinicalTrials.gov (NCT02427464) Phase 3 Gene Therapy for Painful Diabetic Neuropathy. U.S. National Institutes of Health.
Ref 529590Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. Eur J Cardiothorac Surg. 2008 Oct;34(4):857-63.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.